Literature DB >> 29155624

Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.

Harriet C Thoeny1, Sebastiano Barbieri1, Johannes M Froehlich1, Baris Turkbey1, Peter L Choyke1.   

Abstract

Patients with prostate cancer who have regional lymph node (LN) metastases face an increased risk of death from disease and are therefore treated aggressively. Surgical LN dissection is the established method of staging regional nodes; however, this invasive technique carries substantial morbidities and a noninvasive imaging method is needed to reduce or eliminate the need for extended pelvic LN dissections (ePLND). Conventional computed tomography and magnetic resonance (MR) imaging have proven insensitive and nonspecific because both use nodal size criteria, which is notoriously inaccurate. Novel imaging techniques such as functional MR imaging by using diffusion-weighted MR imaging, MR lymphography with iron oxide particles, and targeted positron emission tomography imaging are currently under development and appear to improve LN staging of prostate cancer. Although progress is being made in staging nodes with imaging, it has not reached the point of replacing ePLND. In this review, the strengths and limitations of these new functional and targeted LN imaging techniques for prostate cancer are discussed. © RSNA, 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29155624      PMCID: PMC5708287          DOI: 10.1148/radiol.2017161517

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  66 in total

1.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

2.  Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases.

Authors:  Rocco Papalia; Giuseppe Simone; Rosario Grasso; Raffaele Augelli; Eliodoro Faiella; Salvatore Guaglianone; Roberto Cazzato; Riccardo Del Vescovo; Mariaconsiglia Ferriero; Bruno Zobel; Michele Gallucci
Journal:  BJU Int       Date:  2011-08-25       Impact factor: 5.588

3.  Changes in Epithelium, Stroma, and Lumen Space Correlate More Strongly with Gleason Pattern and Are Stronger Predictors of Prostate ADC Changes than Cellularity Metrics.

Authors:  Aritrick Chatterjee; Geoffrey Watson; Esther Myint; Paul Sved; Mark McEntee; Roger Bourne
Journal:  Radiology       Date:  2015-06-23       Impact factor: 11.105

4.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

Review 5.  Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.

Authors:  Hamm Bernd; Eric De Kerviler; Sophie Gaillard; Bruno Bonnemain
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

6.  The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.

Authors:  Bruce S Spinowitz; Michael H Schwenk; Paula M Jacobs; W Kline Bolton; Mark R Kaplan; Chaim Charytan; Marilyn Galler
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

7.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

8.  Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging.

Authors:  Harriet C Thoeny; Johannes M Froehlich; Maria Triantafyllou; Juerg Huesler; Lauren J Bains; Peter Vermathen; Achim Fleischmann; Urs E Studer
Journal:  Radiology       Date:  2014-06-02       Impact factor: 11.105

9.  18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

Authors:  Cristina Nanni; Riccardo Schiavina; Eugenio Brunocilla; Marco Borghesi; Valentina Ambrosini; Lucia Zanoni; Giorgio Gentile; Valerio Vagnoni; Daniele Romagnoli; Giuseppe Martorana; Stefano Fanti
Journal:  Clin Genitourin Cancer       Date:  2013-10-14       Impact factor: 2.872

10.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

View more
  16 in total

1.  Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Authors:  Baris Turkbey; Marcin Czarniecki; Joanna H Shih; Stephanie A Harmon; Piyush K Agarwal; Andrea B Apolo; Deborah E Citrin; James L Gulley; Mukesh Harisinghani; Ravi A Madan; Adam R Metwalli; Edmond Paquette; Peter A Pinto; Soroush Rais-Bahrami; Lindsay S Rowe; Bradford J Wood; Paula M Jacobs; Liza Lindenberg; William Dahut; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2019-10-15       Impact factor: 3.959

Review 2.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 3.  Novel Imaging in Detection of Metastatic Prostate Cancer.

Authors:  Clayton P Smith; Anna Laucis; Stephanie Harmon; Esther Mena; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 4.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

5.  Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies.

Authors:  N Sushentsev; H Martin; Y Rimmer; T Barrett
Journal:  Clin Transl Oncol       Date:  2019-03-13       Impact factor: 3.405

6.  Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.

Authors:  Erik Rud; Daniyal Noor; Kristina Flor Galtung; Fredrik Ottosson; Maciej Jacewicz; Eduard Baco; Peter Mæhre Lauritzen
Journal:  Eur Radiol       Date:  2022-08-08       Impact factor: 7.034

Review 7.  Recent Advancements in CT and MR Imaging of Prostate Cancer.

Authors:  Asha Daryanani; Baris Turkbey
Journal:  Semin Nucl Med       Date:  2021-12-18       Impact factor: 4.802

Review 8.  The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.

Authors:  Marijo Bilusic; David J Einstein; Fatima H Karzai; William L Dahut; James L Gulley; Jeanny B Aragon-Ching; Ravi A Madan
Journal:  Urol Clin North Am       Date:  2020-11       Impact factor: 2.241

Review 9.  Sentinel lymph node imaging in urologic oncology.

Authors:  Sherif Mehralivand; Henk van der Poel; Alexander Winter; Peter L Choyke; Peter A Pinto; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2018-10

Review 10.  Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer.

Authors:  Marcin Czarniecki; Filippo Pesapane; Bradford J Wood; Peter L Choyke; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.